Kidney stone pathophysiology: Difference between revisions
Line 19: | Line 19: | ||
*[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells]. | *[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells]. | ||
*The progression to [disease name] usually involves the [molecular pathway]. | *The progression to [disease name] usually involves the [molecular pathway]. | ||
* | *The following table summarizes major mechanism of stone formation:<ref name="Moe2006">{{cite journal|last1=Moe|first1=Orson W|title=Kidney stones: pathophysiology and medical management|journal=The Lancet|volume=367|issue=9507|year=2006|pages=333–344|issn=01406736|doi=10.1016/S0140-6736(06)68071-9}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Type of stone | ! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Type of stone | ||
Line 28: | Line 28: | ||
|- | |- | ||
| style="background:#4479BA; color: #FFFFFF;" align="center" |All stones | | style="background:#4479BA; color: #FFFFFF;" align="center" |All stones | ||
|Low urine volume (raises production of solutes) | |Low urine volume | ||
(raises production of solutes) | |||
|Reduced intake or increased loss of water | |Reduced intake or increased loss of water | ||
|Renal water conservation | |Renal water conservation | ||
Line 37: | Line 38: | ||
|- | |- | ||
| rowspan="16" style="background:#4479BA; color: #FFFFFF;" align="center" |Calcium stones | | rowspan="16" style="background:#4479BA; color: #FFFFFF;" align="center" |Calcium stones | ||
| rowspan="6" |Hypercalciuria (raises saturation of calcium salts) | | rowspan="6" |[[Hypercalciuria]] | ||
|Absorptive hypercalciuria | (raises saturation of calcium salts) | ||
|Absorptive [[hypercalciuria]] | |||
|Increased absorption in gut | |Increased absorption in gut | ||
| rowspan="6" |Calcium oxalate or phosphate | | rowspan="6" |[[Calcium oxalate]] or [[phosphate]] | ||
|Urine calcium concentrations >6 mmol/L (240 mg) per day | |Urine calcium concentrations >6 mmol/L (240 mg) per day | ||
|- | |- | ||
|Hyperparathyroidism | |[[Hyperparathyroidism]] | ||
|Increased absorption in gut and bone release | |Increased absorption in gut and bone release | ||
|High concentrations of parathyroid hormone | |High concentrations of [[parathyroid hormone]] | ||
|- | |- | ||
| | |Immobilization | ||
|Bone resorption | |[[Bone resorption]] | ||
|High concentrations of vitamin D | |High concentrations of [[vitamin D]] | ||
|- | |- | ||
|Excess of sodium in the diet | |Excess of [[sodium]] in the diet | ||
|Sodium-induced physiological renal calcium leak. Possible component of gut hyperabsorption | |Sodium-induced physiological renal calcium leak. Possible component of gut hyperabsorption | ||
|Urine sodium concentrations >200 mmol/L per day | |Urine sodium concentrations >200 mmol/L per day | ||
|- | |- | ||
|Excess of protein or acid in diet | |Excess of [[protein]] or acid in diet | ||
|Protein-induced bone loss and renal leak. | |Protein-induced bone loss and renal leak. | ||
| | | | ||
* Urine ammonium iron concentrations high | * Urine [[ammonium]] iron concentrations high | ||
* Urine sulfate concentrations high | * Urine [[sulfate]] concentrations high | ||
* Urine pH low | * [[Urine pH]] low | ||
* Urine citrate concentrations <1·7 mmol/L per day | * Urine [[citrate]] concentrations <1·7 mmol/L per day | ||
|- | |- | ||
|Range of monogenic disorders | |Range of monogenic disorders | ||
Line 67: | Line 69: | ||
| | | | ||
|- | |- | ||
| rowspan="2" |Hypocitraturia (raises levels of ionised calcium and reduces inhibitor activity against calcium salts) | | rowspan="2" |[[Hypocitraturia]] | ||
|Renal tubular acidosis (distal type) | (raises levels of ionised calcium and reduces inhibitor activity against calcium salts) | ||
|Renal | |[[Renal tubular acidosis]] (distal type) | ||
|Calcium phosphate | |Renal defense of [[acid-base balance]] | ||
|[[Calcium phosphate]] | |||
| | | | ||
* Urine citrate concentrations <1·7 mmol/L per day | * Urine [[citrate]] concentrations <1·7 mmol/L per day | ||
* Urine pH high | * Urine pH high | ||
|- | |- | ||
|High acid load (absence of detectable acidemia) | |High acid load (absence of detectable acidemia) | ||
|Physiological hypocitraturia | |Physiological [[hypocitraturia]] | ||
|Calcium oxalate or phosphate | |[[Calcium oxalate]] or phosphate | ||
| | | | ||
* Urine citrate concentrations <1·7 mmol/L per day | * Urine [[citrate]] concentrations <1·7 mmol/L per day | ||
* Urine pH low | * Urine pH low | ||
|- | |- | ||
| rowspan="3" |Hyperoxaluria (raises saturation of calcium oxalate) | | rowspan="3" |[[Hyperoxaluria]] | ||
|Excess of oxalate in diet | (raises saturation of [[calcium oxalate]]) | ||
|Excess of [[oxalate]] in diet | |||
|Increased delivery of luminal oxalate | |Increased delivery of luminal oxalate | ||
| rowspan="8" |Calcium oxalate | | rowspan="8" |[[Calcium oxalate]] | ||
|Urine oxalate concentrations >70·7 mmol/L per day | |Urine oxalate concentrations >70·7 mmol/L per day | ||
|- | |- | ||
Line 93: | Line 97: | ||
|- | |- | ||
|Increased production of endogenous oxalate | |Increased production of endogenous oxalate | ||
|Primary hyperoxaluria (type 1 and type 2) | |[[Primary hyperoxaluria]] (type 1 and type 2) | ||
| | | | ||
|- | |- | ||
| rowspan="5" |Hyperuricosuria (sodium urate precipitation causes | | rowspan="5" |[[Hyperuricosuria]] | ||
|High purine intake | (sodium urate precipitation causes crystallization of calcium salts) | ||
|High [[purine]] intake | |||
| rowspan="4" |Raised production and urinary excretion of sodium and urate | | rowspan="4" |Raised production and urinary excretion of sodium and urate | ||
| | | | ||
Line 103: | Line 108: | ||
* Hyperuricaemia | * Hyperuricaemia | ||
|- | |- | ||
|Myeloproliferative diseases | |[[Myeloproliferative disease|Myeloproliferative diseases]] | ||
| | | | ||
|- | |- | ||
|Enzymatic defects | |Enzymatic defects | ||
|Urine uric acid concentrations >600 mg per day | |Urine [[uric acid]] concentrations >600 mg per day | ||
|- | |- | ||
|Uricosuric drugs | |[[Uricosuric]] drugs | ||
|Hypouricaemia | |Hypouricaemia | ||
|- | |- | ||
|Genetic primary renal leak | |Genetic primary renal leak | ||
|Increased excretion of uric acid | |Increased excretion of [[uric acid]] | ||
| | | | ||
|- | |- | ||
| style="background:#4479BA; color: #FFFFFF;" align="center" |Uric acid stones | | style="background:#4479BA; color: #FFFFFF;" align="center" |Uric acid stones | ||
|Low urine pH or hyperuricosuria | |Low urine pH or [[hyperuricosuria]] | ||
| | | | ||
* High acid load | * High acid load | ||
* Metabolic syndrome | * [[Metabolic syndrome]] | ||
|Titrates urate to poorly soluble uric acid | |Titrates [[urate]] to poorly soluble uric acid | ||
|Uric acid | |[[Uric acid]] | ||
|Urine pH <5·5 | |Urine pH <5·5 | ||
|- | |- | ||
| style="background:#4479BA; color: #FFFFFF;" align="center" |Cystine stones | | style="background:#4479BA; color: #FFFFFF;" align="center" |Cystine stones | ||
|Cystinuria | |[[Cystinuria]] | ||
|Congenital mutations of dibasic aminoacid transporter subunits rBAT and b0+AT | |Congenital mutations of dibasic aminoacid transporter subunits rBAT and b0+AT | ||
|Renal leak of basic aminoacids | |Renal leak of basic aminoacids | ||
|Cystine | |[[Cystine]] | ||
|Urine concentrations of cystine high (>150 μmol/mmol creatinine) | |Urine concentrations of [[cystine]] high (>150 μmol/mmol creatinine) | ||
|- | |- | ||
| style="background:#4479BA; color: #FFFFFF;" align="center" |Infection stones | | style="background:#4479BA; color: #FFFFFF;" align="center" |Infection stones | ||
|Urinary tract infection | |[[Urinary tract infection]] | ||
|Urea-splitting organisms | |Urea-splitting organisms | ||
|Production of ammonium and bicarbonate from urea | |Production of [[ammonium]] and [[bicarbonate]] from [[urea]] | ||
| | | | ||
* Magnesium ammonium phosphate | * Magnesium [[ammonium phosphate]] | ||
* Carbonate apatite | * Carbonate apatite | ||
| | | |
Revision as of 22:15, 20 June 2018
https://https://www.youtube.com/watch?v=uloDkeBOxGQ%7C350}} |
Kidney stone Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Kidney stone pathophysiology On the Web |
American Roentgen Ray Society Images of Kidney stone pathophysiology |
Risk calculators and risk factors for Kidney stone pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Pathophysiology
Pathogenesis
- It is understood that nephrolithiasis is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
- [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
- Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
- [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
- The progression to [disease name] usually involves the [molecular pathway].
- The following table summarizes major mechanism of stone formation:[1]
Type of stone | Cause | Pathophysiology | Stone composition | Labs | |
---|---|---|---|---|---|
All stones | Low urine volume
(raises production of solutes) |
Reduced intake or increased loss of water | Renal water conservation | All stones |
|
Calcium stones | Hypercalciuria
(raises saturation of calcium salts) |
Absorptive hypercalciuria | Increased absorption in gut | Calcium oxalate or phosphate | Urine calcium concentrations >6 mmol/L (240 mg) per day |
Hyperparathyroidism | Increased absorption in gut and bone release | High concentrations of parathyroid hormone | |||
Immobilization | Bone resorption | High concentrations of vitamin D | |||
Excess of sodium in the diet | Sodium-induced physiological renal calcium leak. Possible component of gut hyperabsorption | Urine sodium concentrations >200 mmol/L per day | |||
Excess of protein or acid in diet | Protein-induced bone loss and renal leak. | ||||
Range of monogenic disorders | Bone loss, gut hyperabsorption, and renal leak in various combinations | ||||
Hypocitraturia
(raises levels of ionised calcium and reduces inhibitor activity against calcium salts) |
Renal tubular acidosis (distal type) | Renal defense of acid-base balance | Calcium phosphate |
| |
High acid load (absence of detectable acidemia) | Physiological hypocitraturia | Calcium oxalate or phosphate |
| ||
Hyperoxaluria
(raises saturation of calcium oxalate) |
Excess of oxalate in diet | Increased delivery of luminal oxalate | Calcium oxalate | Urine oxalate concentrations >70·7 mmol/L per day | |
Bowel pathology | Reduced formation of luminal calcium and calcium-oxalate complex | ||||
Increased production of endogenous oxalate | Primary hyperoxaluria (type 1 and type 2) | ||||
Hyperuricosuria
(sodium urate precipitation causes crystallization of calcium salts) |
High purine intake | Raised production and urinary excretion of sodium and urate |
| ||
Myeloproliferative diseases | |||||
Enzymatic defects | Urine uric acid concentrations >600 mg per day | ||||
Uricosuric drugs | Hypouricaemia | ||||
Genetic primary renal leak | Increased excretion of uric acid | ||||
Uric acid stones | Low urine pH or hyperuricosuria |
|
Titrates urate to poorly soluble uric acid | Uric acid | Urine pH <5·5 |
Cystine stones | Cystinuria | Congenital mutations of dibasic aminoacid transporter subunits rBAT and b0+AT | Renal leak of basic aminoacids | Cystine | Urine concentrations of cystine high (>150 μmol/mmol creatinine) |
Infection stones | Urinary tract infection | Urea-splitting organisms | Production of ammonium and bicarbonate from urea |
|
Genetics
- Nephrolithiasis can be passed on to following generations due to rare causes of hypercalciuria:
- Hereditary distal renal tubular acidosis
- Dent disease
- Bartter syndrome types III and IV
- Autosomal dominant hypocalcemic hypercalciuria
- Familial hypomagnesemia
Associated Conditions
Gross Pathology
- On gross pathology, the characteristic findings of nephrolithiasis are:
- Location = 80% unilateral, usually in calyces, pelvis or bladder
- Size=variable, 2-3 mm usually
- All stones contain an organic matrix of mucoprotein
- Shape:
- Struvite stone= staghorn calculus
-
Nephrolithiasis, Source: Wikimedia commons[2]
-
Staghorn shape of struvite stones, Source: Wikimedia commons[3]
-
Renal calculi, different shapes and sizes, Source: Wikimedia commons[4]
-
Kidney stone with a maximum dimension of 5mm, Source: Wikimedia commons[5]
Microscopic Pathology
- On microscopic histopathological analysis, the characteristic findings of nephrolithiasis are:
- Shapes of different stones/crystals are different:
- Cysteine= hexagonal
- Struvite= coffin lid shape
- Calcium oxalate= pyramid shape
- Calcium oxalate= dumbbell shape
- Uric acid= rectangular/rhomboidal
- Oxalate crystals are highlighted by polarized light
- Foreign body giant cells and macrophages are seen with the stones
- Shapes of different stones/crystals are different:
-
Type of stones. Light microscopy of urine crystals. (A) Hexagonal cystine crystal (200X); (B) coffin-lid shaped struvite crystals (200X); (C) pyramid-shaped calcium oxalate dehydrate crystals (200X); (D) dumbbell-shaped calcium oxalate monohydrate crystal (400X); (E) rectangular uric acid crystals (400X); and (F) rhomboidal uric acid crystals (400X).[6]
-
Deposits of oxalate with variable size and form; they occupy mainly distal tubules. The asterisks indicate proximal tubules, which usually do not contain these crystals, H&E seen with polarized light, X200[7]
-
Medullary interstitial urate crystal deposits in chronic nephropathy by urates as seen after Masson's trichome stain X400[8]
-
Calcium oxalate dihydrate crystals under Scanning Electron Micrograph (SEM) taken at 30 KV. Source: Wikimedia commons[9]
-
Density-dependent color scanning electron micrograph of kidney stone, Source: Wikimedia commons[10]
References
- ↑ Moe, Orson W (2006). "Kidney stones: pathophysiology and medical management". The Lancet. 367 (9507): 333–344. doi:10.1016/S0140-6736(06)68071-9. ISSN 0140-6736.
- ↑ By Amadalvarez - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=46706235
- ↑ By H. Zell [GFDL (http://www.gnu.org/copyleft/fdl.html) or CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)], from Wikimedia Commons
- ↑ By Jakupica - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=45324355
- ↑ By RJHall - Own work, Public Domain, https://commons.wikimedia.org/w/index.php?curid=4070842
- ↑ Han H, Segal AM, Seifter JL, Dwyer JT (July 2015). "Nutritional Management of Kidney Stones (Nephrolithiasis)". Clin Nutr Res. 4 (3): 137–52. doi:10.7762/cnr.2015.4.3.137. PMC 4525130. PMID 26251832.
- ↑ http://kidneypathology.com/Imagenes/Diabetes/Oxalato.4.w.jpg
- ↑ http://www.kidneypathology.com/English_version/Diabetes_and_others.html
- ↑ By Kempf EK - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=18036112
- ↑ By Sergio Bertazzo - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=45316797